Related Experiment Video
Updated: Sep 13, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Managing HBV/HIV coinfection: from diagnostics to long-acting antiretroviral therapy
Aleksandra Raczyńska1, Martyna Lara1,2, Anna Ruszecka3
1Department of Infectious Diseases, University Hospital, Kraków, Poland.
Abstract:
Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection accelerates liver disease progression and increases the risk of hepatocellular carcinoma (HCC). Lifelong HBV-active antiretroviral therapy is the cornerstone of management, while occult HBV infection and isolated anti-HBc serology require careful monitoring, particularly when switching to long-acting regimens lacking HBV activity. Comprehensive diagnostics, including HBV DNA testing, fibrosis assessment, and evaluation of serological profiles, are essential for optimal care. Vaccination with next-generation HBV vaccines (ex. CpG adjuvant, multiantigenic), provides superior immunogenicity and should be prioritized in people living with HIV, especially in prior nonresponders. Regular HCC screening is recommended in individuals with advanced liver disease to enable early detection and intervention. This review summarizes current evidence on diagnostics, therapy, vaccination, monitoring, and cancer prevention, providing practical recommendations to improve outcomes in HIV/HBV coinfected populations.
Related Concept Videos
Retrovirus Life Cycles
Hepatitis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Viral Hepatitis I: Introduction
Size and Structure of Viral Genomes
Antiviral Nucleoside Inhibitors
